公开(公告)号：US12037355B2

公开(公告)日：2024-07-16

申请号：US18180421

申请日：2023-03-08

Applicant: ADJUVANCE TECHNOLOGIES, INC. ,  MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： David Y. Gin ,  Eric Chea ,  Alberto Fernandez-Tejada ,  Jeffrey Gardner ,  Jason Lewis ,  Philip Livingston ,  J. Tyler Martin ,  Lars Nordstroem ,  Naga Vara Kishore Pillarsetty ,  Govind Ragupathi ,  Derek Tan

IPC: C07H1/00 ,  A61K31/7024 ,  A61K39/02 ,  A61K39/08 ,  A61K39/39 ,  A61P31/04 ,  C07H13/04 ,  C07H13/06 ,  C07H13/08 ,  C07J63/00 ,  A61K39/00 ,  A61K39/10

CPC classification number: C07H1/00 ,  A61K31/7024 ,  A61K39/08 ,  A61K39/099 ,  A61K39/39 ,  A61P31/04 ,  C07H13/04 ,  C07H13/06 ,  C07H13/08 ,  C07J63/008 ,  A61K2039/10 ,  A61K2039/55583

Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

公开(公告)号：US20240197863A1

公开(公告)日：2024-06-20

申请号：US18287248

申请日：2022-04-19

Applicant: KM Biologics Co., Ltd.

Inventor： Shun YAMASHITA ,  Tatsuya SHIRAI ,  Kazuhiro DAIMON ,  Tomohiro MINODA ,  Shinji AKASAKI ,  Kanae ISHIKAWA ,  Haruna IWATA

IPC: A61K39/29 ,  A61K39/00 ,  A61K39/02 ,  A61K39/05 ,  A61K39/08 ,  A61K39/13 ,  A61K39/145

CPC classification number: A61K39/292 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/13 ,  A61K39/145 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55544 ,  A61K2039/70

Abstract: Provided is a liquid formulation of a six combined vaccine containing DPT-IPV-Hib-HBs, in which a HBs antigen is stably adsorbed and retained to an aluminum adjuvant, and PRP as a Hib antigen is stably coupled and retained to a carrier protein. A method for producing a stable liquid formulation of a six combined vaccine against diphtheria, pertussis, tetanus, polio, Haemophilus influenzae type b (Hib), and hepatitis B (HepB), the method comprising the following steps of: (1) mixing diphtheria toxoid (D) and tetanus toxoid (T) with an aluminum adjuvant to produce a DT adjuvant; (2) mixing a hepatitis B surface (HBs) antigen with the DT adjuvant obtained in step (1) to produce a DT-HBs adjuvant; (3) mixing a pertussis antigen (P) with the DT-HBs adjuvant obtained in step (2) to produce a DPT-HBs adjuvant; (4) mixing inactivated poliovirus (IPV) with the DPT-HBs adjuvant obtained in step (3) to produce a DPT-IPV-HBs adjuvant; (5) adding a succinate phosphate buffer to the DPT-IPV-HBs adjuvant obtained in step (4), and then adding PRP (PRP-T conjugate) as a Hib antigen to produce a mixture of DPT-IPV-Hib-HBs adjuvant and PRP-T conjugate; and (6) adjusting pH of the mixture of DPT-IPV-Hib-HBs adjuvant and PRP-T conjugate obtained in step (5) to 5.4 to 5.9.

公开(公告)号：US20240189410A1

公开(公告)日：2024-06-13

申请号：US18535116

申请日：2023-12-11

Applicant: Pfizer Inc.

Inventor： Annaliesa Sybil Anderson ,  Marina A. Gonzalez-Garis ,  Lei Hu ,  Isis Kanevsky ,  Paul Arthur Liberator ,  Justin Keith Moran ,  Lynn Marie Phelan ,  Michael William Pride ,  Shuai Shi ,  Naveen Surendran

IPC: A61K39/08 ,  A61K39/39 ,  A61P31/04

CPC classification number: A61K39/08 ,  A61K39/39 ,  A61P31/04 ,  A61K2039/55561

Abstract: The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and/or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relate to a methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two times.

公开(公告)号：US12005102B2

公开(公告)日：2024-06-11

申请号：US17091553

申请日：2020-11-06

Applicant: AC Immune SA

Inventor： Emma Fiorini ,  Marija Vukicevic Verhille ,  Maria Pihlgren Bosch

IPC: A61K39/395 ,  A61K9/127 ,  A61K39/00 ,  A61K39/05 ,  A61K39/08 ,  A61K39/245 ,  A61K39/39 ,  A61P25/28 ,  C07K14/005

CPC classification number: A61K39/0007 ,  A61K9/127 ,  A61K39/0003 ,  A61K39/0005 ,  A61K39/05 ,  A61K39/08 ,  A61K39/245 ,  A61K39/39 ,  A61P25/28 ,  C07K14/005 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/58 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K2319/33 ,  C07K2319/55 ,  C12N2710/16232 ,  C12N2710/16234 ,  C12N2760/16033

Abstract: A liposomal vaccine composition comprises a β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.

公开(公告)号：US20240115696A1

公开(公告)日：2024-04-11

申请号：US18338847

申请日：2023-06-21

Applicant: JN Biosciences, LLC ,  Abmuno Therapeutics, LLC

Inventor： J. Yun Tso ,  Naoya Tsurushita ,  Omar Duramad

IPC: A61K39/395 ,  A61K39/08 ,  A61K39/085 ,  A61K39/39 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39541 ,  A61K39/08 ,  A61K39/085 ,  A61K39/39 ,  A61K39/3955 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/2878 ,  C07K16/2896 ,  C07K16/3061 ,  A61K2039/545 ,  C07K2317/734

Abstract: The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.

公开(公告)号：US11911449B2

公开(公告)日：2024-02-27

申请号：US17322901

申请日：2021-05-18

Applicant: REVANCE THERAPEUTICS, INC.

Inventor： Stewart A. Thompson ,  Curtis L. Ruegg ,  Jacob M. Waugh

IPC: A61K38/48 ,  A61K8/49 ,  A61K8/60 ,  A61K8/64 ,  A61K39/08 ,  A61K8/02 ,  A61K8/66 ,  A61K8/84 ,  A61K9/14 ,  A61K9/19 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  A61K47/42 ,  A61Q19/00 ,  A61Q19/08 ,  C07K14/33 ,  A61K8/90

CPC classification number: A61K38/4893 ,  A61K8/022 ,  A61K8/4946 ,  A61K8/4973 ,  A61K8/4993 ,  A61K8/60 ,  A61K8/602 ,  A61K8/64 ,  A61K8/66 ,  A61K8/84 ,  A61K8/90 ,  A61K9/14 ,  A61K9/19 ,  A61K39/08 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  A61K47/42 ,  A61Q19/008 ,  A61Q19/08 ,  C07K14/33 ,  C12Y304/24069 ,  Y02A50/30

Abstract: This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.

公开(公告)号：US20240000913A1

公开(公告)日：2024-01-04

申请号：US18318093

申请日：2023-05-16

Applicant: Zoetis Services LLC

Inventor： Paul Joseph Dominowski ,  Dennis L. Foss ,  Guillermo Gallo ,  John Morgan Hardham ,  Richard Lee Krebs ,  Sandra Ann Marie Lightle ,  Suman Mahan ,  Sangita Mediratta ,  Kaori Mohr ,  Duncan Mwangi ,  Sharath K. Rai ,  Sarah A. Salmon ,  Shaunak Vora ,  Lauren Wilmes

IPC: A61K39/09 ,  A61K39/00 ,  A61K39/012 ,  A61K39/108 ,  A61K39/05 ,  A61K39/08 ,  A61K39/118 ,  A61K39/39 ,  A61K39/002 ,  A61K39/085 ,  A61K39/12 ,  G01N33/569

CPC classification number: A61K39/092 ,  G01N2469/10 ,  A61K39/012 ,  A61K39/0258 ,  A61K39/05 ,  A61K39/08 ,  A61K39/118 ,  A61K39/39 ,  A61K39/0005 ,  A61K39/002 ,  A61K39/085 ,  A61K39/0002 ,  A61K39/12 ,  G01N33/56944 ,  A61K2039/552 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/55583 ,  Y02A50/30 ,  G01N2333/315 ,  A61K39/0003

Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.

公开(公告)号：US20230340153A1

公开(公告)日：2023-10-26

申请号：US18296265

申请日：2023-04-05

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Mark W. SLEEMAN ,  Joel H. MARTIN ,  Tammy T. HUANG ,  Douglas MACDONALD

IPC: C07K16/40 ,  A61K39/08 ,  G01N33/569 ,  C12N15/09 ,  C07K16/12

CPC classification number: C07K16/40 ,  A61K39/08 ,  G01N33/56911 ,  C12N15/09 ,  C12Y304/21061 ,  C07K16/1282 ,  A61K2039/505

Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

公开(公告)号：US11795190B2

公开(公告)日：2023-10-24

申请号：US16957173

申请日：2018-12-29

Applicant: NATIONAL RESEARCH COUNCIL OF CANADA ,  THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

Inventor： Janelle Sauvageau ,  Andrew Cox ,  Xinyi Guo ,  Scott Gray-Owen

IPC: C07H11/04 ,  A61K39/00 ,  A61K39/002 ,  A61K39/005 ,  A61K39/008 ,  A61K39/015 ,  A61K39/02 ,  A61K39/108 ,  A61K39/112 ,  A61K39/08 ,  A61K39/085 ,  A61K39/09 ,  A61K39/095 ,  A61K39/118 ,  A61K39/125 ,  A61K39/145 ,  A61K39/15 ,  A61K39/155 ,  A61K39/205 ,  A61K39/215 ,  A61K39/23 ,  A61K39/235 ,  A61K39/39 ,  A61K45/06 ,  C07H13/00 ,  A61K47/54

CPC classification number: C07H11/04 ,  A61K39/002 ,  A61K39/005 ,  A61K39/008 ,  A61K39/0011 ,  A61K39/015 ,  A61K39/0208 ,  A61K39/0225 ,  A61K39/0233 ,  A61K39/0258 ,  A61K39/0275 ,  A61K39/0283 ,  A61K39/0291 ,  A61K39/08 ,  A61K39/085 ,  A61K39/092 ,  A61K39/095 ,  A61K39/099 ,  A61K39/118 ,  A61K39/125 ,  A61K39/145 ,  A61K39/15 ,  A61K39/155 ,  A61K39/205 ,  A61K39/215 ,  A61K39/23 ,  A61K39/235 ,  A61K39/39 ,  A61K45/06 ,  A61K47/549 ,  C07H13/00

Abstract: Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.

公开(公告)号：US11793869B2

公开(公告)日：2023-10-24

申请号：US16597964

申请日：2019-10-10

Applicant: SERUM INSTITUTE OF INDIA PVT LTD

Inventor： Rajeev Mhalasakant Dhere ,  Sambhaji Shankar Pisal ,  Jagdish Kamalaji Zade ,  Rajendra Narayan Sabale ,  Hitesh Kumar Malviya ,  Sunil Mahor ,  Chetan Vilasrao Joshi

IPC: A61K39/13 ,  A61K39/04 ,  A61K39/08 ,  A61K39/102 ,  A61K39/39 ,  C12N7/00 ,  A61K39/02 ,  A61K39/05 ,  A61K39/29 ,  A61K39/00

CPC classification number: A61K39/13 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/102 ,  A61K39/292 ,  A61K39/39 ,  C12N7/00 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10034 ,  C12N2770/32634

Abstract: The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions.